The Lombardi Comprehensive Cancer Center (Lombardi) participates in a wide range of innovative, feasibility, or proof-of- principle trials originating from its research programs. Enrollment in these studies has remained stable during the last grant period. The conduct of these studies is supported by research nursing and data management provided by the Clinical Research Management Office (CRMO). Research nursing focuses solely on the eligibility, consenting, and management of patients on clinical trials all of which is increasingly difficult in today's medical and regulatory environment In addition to its participation in the scope of high-priority clinical trials, Lombardi has conducted a series of innovative phase I trials of cancer vaccines and targeted agents that have provided important information on the mechanisms and clinical efficacy of these agents. These trials are among an extensive portfolio of phase I studies. The interaction of basic science and clinical programs has resulted in the testing of a series of agents that have been developed at Lombardi. The strong emphasis in translational research and drug development is reflected in the accomplishment of Lombardi investigators who have developed and brought to trial targeted agents, growth factor inhibitors, and radiation sensitizing agents. Lombardi continues to play a major role in the treatment and prevention of breast cancer. Selected, high priority clinical trials are given cancer center funding to support their execution. Such funds may come from the CCSG or from institutional sources. Regular Drug Discovery and Developmental Therapeutics (3DT) Program meetings include the presentation of new clinical trial concepts to a multidisciplinary group that includes 3DT members and members of other CCSG programs. The group prioritizes the trials, and the 3DT Program Leaders propose CCSG support to the Lombardi Director, who then assigns funds with the counsel of the Associate Directors and the Senior Operational Leadership Team.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-20
Application #
8739836
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-15
Project End
2014-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
20
Fiscal Year
2013
Total Cost
$35,708
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
AlHossiny, Midrar; Luo, Linlin; Frazier, William R et al. (2016) Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. Cancer Res 76:3376-86
Lai, Chih-Hsin; Lai, Ying-Jung J; Chou, Feng-Pai et al. (2016) Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in Lactation. PLoS One 11:e0152904
Brown, Lindsay; Gutherz, Samuel; Kulick, Catherine et al. (2016) Profile of retigabine-induced neuronal apoptosis in the developing rat brain. Epilepsia 57:660-70
Chung, Arlene E; Jensen, Roxanne E; Basch, Ethan M (2016) Leveraging Emerging Technologies and the ""Internet of Things"" to Improve the Quality of Cancer Care. J Oncol Pract 12:863-866
Taylor, Kathryn L; Hoffman, Richard M; Davis, Kimberly M et al. (2016) Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiol Biomarkers Prev 25:1240-50
Hunegnaw, Ruth; Vassylyeva, Marina; Dubrovsky, Larisa et al. (2016) Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation. Arterioscler Thromb Vasc Biol 36:1758-71
Boca, Simina M; Nishida, Maki; Harris, Michael et al. (2016) Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS One 11:e0153461
Allen, Megan; Ghosh, Suhasini; Ahern, Gerard P et al. (2016) Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1. Sci Rep 6:35497
Cheema, Amrita K; Maier, Irene; Dowdy, Tyrone et al. (2016) Chemopreventive Metabolites Are Correlated with a Change in Intestinal Microbiota Measured in A-T Mice and Decreased Carcinogenesis. PLoS One 11:e0151190
Spikol, Emma D; Laverriere, Caroline E; Robnett, Maya et al. (2016) Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics. Diseases 4:

Showing the most recent 10 out of 883 publications